We are live on
!
Find out more
BCM
Burrage Capital Management Portfolio holdings
AUM
$99.7M
1-Year Est. Return
66.05%
This Fund
S&P 500
This Quarter
Est. Return
-23.88%
1 Year Est. Return
+66.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$102M
AUM Growth
-$47.6M
(-32%)
Cap. Flow
+$663K
Cap. Flow
% of AUM
0.65%
Top 10 Holdings %
Top 10 Hldgs %
57.94%
Holding
38
New
9
Increased
8
Reduced
13
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regenxbio
RGNX
|
+$4.79M |
| 2 |
TECX
Tectonic Therapeutic
TECX
|
+$4.43M |
| 3 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$4.1M |
| 4 |
Cytokinetics
CYTK
|
+$4.06M |
| 5 |
AIMT
Aimmune Therapeutics
AIMT
|
+$2.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARQL
Arqule Inc
ARQL
|
+$11.9M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$6.09M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$3.72M |
| 4 |
US Physical Therapy
USPH
|
+$2.46M |
| 5 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$2.29M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EPZM
1
DELISTED
Epizyme, Inc
EPZM
| $12.5M | 12.34% |
893,698
-71,821
| -7% | -$1.54M |
|
2
PTC Therapeutics
PTCT
$6.52B
| $8.16M | 8.03% |
181,237
-14,488
| -7% | -$729K |
|
3
OrthoPediatrics
KIDS
$493M
| $6.67M | 6.57% |
171,113
-14,505
| -8% | -$650K |
|
4
NeoGenomics
NEO
$1.9B
| $5.24M | 5.16% |
192,277
-6,071
| -3% | -$182K |
|
|
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.99M | 4.91% |
1,521,382
-130,089
| -8% | -$760K |
|
6
AnaptysBio
ANAB
$1.72B
| $4.48M | 4.41% |
331,919
-28,181
| -8% | -$427K |
|
|
LITS
7
Lite Strategy Inc
LITS
$33.6M
| $4.47M | 4.4% |
150,903
-5,347
| -3% | -$214K |
|
|
YMAB
8
DELISTED
Y-mAbs Therapeutics
YMAB
| $4.41M | 4.34% |
171,788
-14,961
| -8% | -$434K |
|
9
Crinetics Pharmaceuticals
CRNX
$8.88B
| $4.02M | 3.96% |
282,272
+76,546
| +37% | +$1.57M |
|
|
GTHX
10
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $3.9M | 3.83% |
378,145
-36,263
| -9% | -$677K |
|
|
11
Cytokinetics
CYTK
$10.9B
| $3.61M | 3.56% |
+318,273
| New | +$4.06M |
|
|
12
Regenxbio
RGNX
$511M
| $3.54M | 3.48% |
+115,000
| New | +$4.79M |
|
13
CytomX Therapeutics
CTMX
$788M
| $3.46M | 3.41% |
482,982
+6,872
| +1% | +$47.9K |
|
|
TVRD
14
Tvardi Therapeutics
TVRD
$30M
| $3.29M | 3.24% |
7,188
-706
| -9% | -$384K |
|
|
TECX
15
Tectonic Therapeutic
TECX
$615M
| $3.27M | 3.22% |
+18,825
| New | +$4.43M |
|
|
TPTX
16
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $3.25M | 3.2% |
+77,172
| New | +$4.1M |
|
17
Korro Bio
KRRO
$177M
| $3.01M | 2.96% |
3,478
+2,408
| +225% | +$2.6M |
|
18
Aurinia Pharmaceuticals
AUPH
$2.05B
| $2.9M | 2.86% |
196,438
+69,905
| +55% | +$1.23M |
|
|
TCDA
19
DELISTED
Tricida, Inc. Common Stock
TCDA
| $2.78M | 2.74% |
131,661
+61,008
| +86% | +$1.96M |
|
20
Xenon Pharmaceuticals
XENE
$6.6B
| $2.11M | 2.08% |
+200,000
| New | +$2.85M |
|
|
APLS
21
DELISTED
Apellis Pharmaceuticals
APLS
| $2.04M | 2.01% |
74,452
-775
| -1% | -$27.5K |
|
|
ZGNX
22
DELISTED
Zogenix, Inc.
ZGNX
| $1.65M | 1.63% |
+70,000
| New | +$2.55M |
|
|
AIMT
23
DELISTED
Aimmune Therapeutics
AIMT
| $1.61M | 1.58% |
+112,546
| New | +$2.88M |
|
|
ADVM
24
DELISTED
Adverum Biotechnologies
ADVM
| $1.56M | 1.53% |
15,601
+12,421
| +391% | +$1.45M |
|
|
AERI
25
DELISTED
Aerie Pharmaceuticals
AERI
| $1.19M | 1.17% |
88,445
-99,531
| -53% | -$1.89M |
|
Similar funds
WCM
CCM
RGM
TCM
RC
AC
QVT
WFWM
Burrage Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Burrage Capital Management held 38 positions worth $102M, down 32% from $149M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Burrage Capital Management's Q1 2020 filing shows 9 new, 8 increased, 13 reduced and 7 closed positions. Its largest new stake was Regenxbio: 115,000 shares worth $3.54M. The largest sale was Arqule Inc, an estimated $11.9M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.
- Burrage Capital Management's largest Q1 2020 buy was Regenxbio: 115,000 shares worth $3.54M.
- Burrage Capital Management added most to Korro Bio in Q1 2020, an estimated $2.6M increase.
- Burrage Capital Management's biggest Q1 2020 reduction was Aerie Pharmaceuticals, cutting an estimated $1.89M.
- Burrage Capital Management fully exited Arqule Inc in Q1 2020, selling an estimated $11.9M.
- Burrage Capital Management's ten largest holdings make up 58% of its $102M portfolio in Q1 2020.
- Burrage Capital Management opened 9 new positions and closed 7 in Q1 2020.
- Burrage Capital Management's portfolio value fell 32% quarter-over-quarter to $102M.
Based on Burrage Capital Management's 13F filing for Q1 2020, filed 14 May 2020.